SIREN : 490072295
NEXMED PHARMA is a French company founded 20 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in PARIS (75016), this company of category ETI shows in 2016 a revenue of 4.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | 4 766 688 € | 4 352 889 € |
| Net income | 12 888 € | 88 708 € | 10 557 € | 62 289 € | 524 272 € |
| EBITDA | N/C | N/C | N/C | -4 718 € | 443 920 € |
| Net margin | N/C | N/C | N/C | 1.3% | 12.0% |
In 2019, NEXMED PHARMA generates positive net income of 13 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2019: 524 k€ -> 13 k€.
12 888 €
The debt ratio (= Financial debt / Equity x 100) stands at 305%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 5%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
304.766%
5.236%
In 2019, the debt ratio of NEXMED PHARMA (304.77) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2019, the financial autonomy of NEXMED PHARMA (5.2%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
The liquidity ratio (= Current assets / Current liabilities) stands at 126.30. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
126.297
In 2019, the liquidity ratio of NEXMED PHARMA (126.30) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 2 571€ to 7 903€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NEXMED PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of NEXMED PHARMA in 2016 is 4.8 M€.
Yes, NEXMED PHARMA generated a net profit of 13 k€ in 2019.
The headquarters of NEXMED PHARMA is located in PARIS (75016), in the department Paris.
The tax return of NEXMED PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NEXMED PHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.